Printer Friendly

Agios Pharmaceuticals presents data from Phase 1 Study of AG-270.

Agios Pharmaceuticals presented the first data from the single agent dose-escalation arm of the Phase 1 study of AG-270 in methylthioadenosine phosphorylase-deleted tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. AG-270 is an investigational, first-in-class methionine adenosyltransferase 2A inhibitor. "The single agent arm of the Phase 1 trial for AG-270 provides the first data from a clinical study of a MAT2A inhibitor," said Rebecca Heist, M.D., Massachusetts General Hospital and an investigator in the study. "These data demonstrate that AG-270 induces reductions in the biomarkers of MAT2A inhibition, notably plasma concentrations of S-adenosylmethionine and tumor levels of symmetrically demethylated arginine, at well tolerated doses. These findings will help guide the dosing and schedule for the next phase of development of AG-270 in combination with taxanes."

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Oct 27, 2019
Previous Article:Merus says MCLA-128 shows 'encouraging' early clinical activity.
Next Article:PG&E to cut power to approximately 940K customers due to weather.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters